摘要银屑病和特应性皮炎是老年人常见的炎症性皮肤病,伴随慢性炎症和免疫失衡,临床治疗面临很多难题.生物制剂和小分子药物的出现显著改善了银屑病和特应性皮炎治疗的效果与安全性,但在老年人中的应用仍面临挑战.老年人常伴有多种共病,诊断需精确和与其他皮肤病鉴别,并应注重组织病理与实验室检测的辅助作用.使用生物制剂和小分子药物治疗老年银屑病和特应性皮炎患者时,应兼顾皮肤症状及全身健康,选择适宜的个体化方案;在治疗过程中须监测药物安全性,尤其须警惕感染、血脂异常及心血管事件等风险.应加强对老年患者的教育以提高对生物制剂及小分子药物的接受度.未来需积累更多临床数据,为老年银屑病和特应性皮炎患者的精准治疗提供依据.

abstractsPsoriasis and atopic dermatitis are common inflammatory skin diseases in the elderly,characterized by chronic inflammation and immune imbalance,making their management challenging.The emergence of biologics and small-molecule drugs has revolutionized the treatment of psoriasis and atopic dermatitis by markedly improving efficacy and safety compared to conventional therapies.However,their application in elderly patients poses challenges.Due to the presence of comorbidities in elderly patients,accurate diagnosis is critical by differentiating psoriasis and atopic dermatitis from other skin diseases,with an emphasis on the auxiliary role of histopathological examination and laboratory tests.In the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs,comprehensive treatment should address both skin symptoms and systemic health,with careful drug selection tailored to individuals.Safety monitoring,particularly vigilance for risks such as infections,lipid abnormalities,and cardiovascular events,is essential during treatment.Education efforts are needed to improve patient knowledge and acceptance of biologics and small molecule drugs.Future research should focus on accumulating clinical data in elderly populations to provide a basis for precision treatment of elderly patients with psoriasis and atopic dermatitis.